News | July 11, 2022
India’s first homegrown mRNA COVID-19 vaccine likely to have low market penetration, says GlobalData
Proportion of the eligible population yet to receive a COVID-19 vaccine is comparatively small
Proportion of the eligible population yet to receive a COVID-19 vaccine is comparatively small
Domestic devices are usually preferred over imported medical devices in the national or regional procurement.
The acquisition continues the growth and expansion course of the ALPLApharma business division established in 2019
Govt committed to supporting pharma companies with industry-friendly policies
NADMED technology is based on proprietary extraction and the individual measurement of NAD metabolites
Both vaccine candidates demonstrated a favorable safety and tolerability profile similar to the Pfizer-BioNTech COVID-19 Vaccine
The Minister directed officials to continue to focus on surveillance and on Whole Genome Sequencing to scan for any possible mutation and also directed for monitoring hospitalizations due to COVID-19 and SARI/ILI cases
An interim analysis of this data shows no significant safety issues and a 91% seroconversion rate at Day 56.
A big boost to healthcare efforts of Ayush through NARIP, CCRAS
The Innovation Explorer database of GlobalData’s Disruptor Intelligence Center highlights how blockchain ensures the authenticity of products thereby, improves trust, traceability, and transparency across key sectors
Subscribe To Our Newsletter & Stay Updated
